High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma

被引:35
|
作者
Shi, Si [1 ]
Li, Xingyu [2 ]
You, Bo [1 ]
Shan, Ying [1 ]
Cao, Xiaolei [2 ]
You, Yiwen [1 ]
机构
[1] Nantong Univ, Dept Otorhinolaryngol Head & Neck Surg, Affiliated Hosp, Nantong, Jiangsu, Peoples R China
[2] Nantong Univ, Dept Pathol, Sch Med, Nantong, Jiangsu, Peoples R China
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 12期
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
nasopharyngeal carcinoma; FGFR4; prognosis; growth; metastasis; GLY388ARG POLYMORPHISM; MESENCHYMAL TRANSITION; FACTOR RECEPTORS; FIBROBLAST; MUTATIONS; PROGNOSIS; BREAST; IDENTIFICATION; SURVIVAL; HEAD;
D O I
10.7150/jca.12825
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: FGF receptor (FGFR) family can be activated by FGFs and play important roles in regulating cell growth, differentiation, migration and angiogenesis. Recent studies suggested that FGFR4 could regulate several processes including tumor progression. Nasopharyngeal carcinoma (NPC) is a malignancy with a high occurrence in Southeast Asia and Southern China. However, the molecule mechanism and the potential roles of FGFR4 in NPC remain unknown Methods: Immunohistochemistry and western blot were used to investigate the expression of FGFR4 in NPC samples. Then we used statistical analysis to evaluate the diagnostic value and the associations of FGFR4 expression with clinical parameters. In vitro studies, the effects of FGFR4 on proliferation and migration of NPC cell line CNE2 were measured by the starvation-refeeding experiment, CCK8 assay, wounding healing assay and transwell migration assay. The changes of the epithelial-mesenchymal transition (EMT) markers in CNE2 cells after knocking down the expression of FGFR4 were measured by Western blot and immunofluorescence analysis. Results: FGFR4 was overexpressed in NPC as compared with the inflammatory tissues. High expression of FGFR4 was correlated with Ki67 expression, clinical stages and prognosis in NPC patients (P<0.05). While in vitro, the upregulation of FGFR4 was accompanied with CNE2 cells released from serum starvation. Moreover, it could increase cell proliferation and migration by regulating EMT markers in CNE2 cells. Conclusion: Our data suggested that FGFR4 might induce NPC progression and act as a potential therapeutic target in NPC.
引用
收藏
页码:1245 / 1254
页数:10
相关论文
共 50 条
  • [21] FGFR4 Y367C: Contributes to a constitutively active FGFR4 and tumor aggressiveness in breast cancer cell line
    Foo, P.
    Ho, H. K.
    Streit, S.
    Ruhe, J. E.
    Hart, S.
    Ullrich, A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 114 - 114
  • [22] Expression of acidic fibroblast growth factor (aFGF) and fibroblast growth factor receptor 4 (FGFR4) in breast fibroadenomas
    La Rosa, S
    Sessa, F
    Colombo, L
    Tibiletti, MG
    Furlan, D
    Capella, C
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (01) : 37 - 41
  • [23] Combined inhibition of FGFR4 and VEGFR signaling enhances efficacy in FGF19 driven hepatocellular carcinoma
    Zhao, Xuesong
    Joshi, Jaya Julie
    Aird, Daniel
    Karr, Craig
    Yu, Kun
    Huang, Chialing
    Colombo, Federico
    Virrankoski, Milena
    Prajapati, Sudeep
    Selvaraj, Anand
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (06): : 2733 - +
  • [24] A role for FGFR4 in growth and survival of Ewing sarcoma cells
    Montoya, Justin J.
    Wai, Daniel H.
    Lee, David W.
    Azorsa, Peter A.
    Pepper, Oliver B.
    Arceci, Robert J.
    Azorsa, David O.
    CANCER RESEARCH, 2017, 77
  • [25] Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
    Lu, Xiaoyun
    Chen, Hao
    Patterson, Adam V.
    Smaill, Jeff B.
    Ding, Ke
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (06) : 2905 - 2915
  • [26] Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
    Miranda, Renata Rezende
    Fu, Ying
    Chen, Xiaojuan
    Perino, John
    Cao, Ping
    Carpten, John
    Chen, Yongheng
    Zhang, Chao
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (20) : 11484 - 11497
  • [27] Exploring GSEA analysis on the biological role of FGFR4 Expression in Clear Cell Renal Cell Carcinoma
    Narisawa, Takafumi
    Suenaga, Shinta
    Takai, Yuki
    Takai, Satoshi
    Ushijima, Masaki
    Yagi, Mayu
    Ito, Hiromi
    Naito, Sei
    Tsuchiya, Norihiko
    CANCER SCIENCE, 2025, 116 : 1471 - 1471
  • [28] Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
    French, Dorothy M.
    Lin, Benjamin C.
    Wang, Manping
    Adams, Camellia
    Shek, Theresa
    Hoetzel, Kathy
    Bolon, Brad
    Ferrando, Ronald
    Blackmore, Craig
    Schroeder, Kurt
    Rodriguez, Luis A.
    Hristopoulos, Maria
    Venook, Rayna
    Ashkenazi, Avi
    Desnoyers, Luc R.
    PLOS ONE, 2012, 7 (05):
  • [29] FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential
    Xie, Hao
    Alem Glison, Diego M.
    Kim, Richard D.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) : 393 - 400
  • [30] Identification of resistance mechanisms to FGFR4 targeted therapy in hepatocellular carcinoma
    Hatlen, Megan A.
    Schmidt-Kittler, Oleg
    Sherwin, Cori-Ann
    Rozsahegyi, Emily
    Rubin, Nooreen
    Sheets, Michael
    Kim, Joseph L.
    Miduturu, Chandra
    Bifulco, Neil
    Brooijmans, Natasja
    Shi, Hongliang
    Guzi, Timothy
    Boral, Andy
    Lengauer, Christoph
    Dorsch, Marion
    Kim, Richard D.
    Kang, Yoon-Koo
    Wolf, Beni B.
    Hoeflich, Klaus P.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)